Researcher Profile

Researcher Profile

Sheldon Holder, PhD, MD

Sheldon Holder, PhD, MD

Assistant Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Genitourinary Cancer
slh51@psu.edu

Research Interests

  • Therapeutics
  • Phosphotransferases
  • Prostatic Neoplasms
  • Neoplasms
  • Renal Cell Carcinoma
  • Urinary Bladder Neoplasms
  • Carcinoma
  • Smokers
  • Castration
  • Drug Therapy
  • Non-Smokers
  • Smoking

Clinical Trials

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Locally Advanced Urothelial Cancer with Selected FGFR Gene Alterations
Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib study of Abemaciclib in Combination with Sunitinib in metastatic RCC
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Observational Study to Determine the Differences in Molecular Characterization between Smokers vs. Non-smokers in Patients with Stage IV Bladder Cancer and their Correlation with Clinical Outcome

Recent Publications

2019

Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04
Wang, M, Chi, G, Bodovski, Y, Holder, SL, Lengerich, EJ, Wasserman, E & McDonald, AC 2020, 'Temporal and spatial trends and determinants of aggressive prostate cancer among Black and White men with prostate cancer', Cancer Causes and Control, vol. 31, no. 1, pp. 63-71. https://doi.org/10.1007/s10552-019-01249-0

2017

Small, J, Washburn, E, Millington, K, Zhu, J & Holder, SL 2017, 'The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors', Oncotarget, vol. 8, no. 56, pp. 95116-95134. https://doi.org/10.18632/oncotarget.19618

2016

Matthew, EM, Zhou, L, Yang, Z, Dicker, DT, Holder, SL, Lim, B, Harouaka, R, Zheng, SY, Drabick, JJ, Lamparella, NE, Truica, CI & El-Deiry, WS 2016, 'A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells', Oncotarget, vol. 7, no. 4, pp. 3662-3676. https://doi.org/10.18632/oncotarget.6657
Al-Marrawi, MY, Mackley, HB, Ali, S, Wagner, H, Joshi, M, Holder, S, Kaag, M, Mallon, C, Talamo, G & Drabick, JJ 2016, 'Consolidation With Radiation or Concurrent Chemo-Radiation After Chemotherapy Results in Durable Complete Remissions of Isolated Nodal Recurrences of Urothelial Cancer: A Case Series and Review', Clinical Genitourinary Cancer, vol. 14, no. 4, pp. e393-e399. https://doi.org/10.1016/j.clgc.2016.01.004
Al-Marrawi, MY & Holder, SL 2016, 'Current immunotherapies for renal cell carcinoma', Current Molecular Pharmacology, vol. 9, no. 3, pp. 252-263. https://doi.org/10.2174/1874467208666150716121116
Joshi, M, Millis, SZ, Arguello, D, Holder, SL, Lamm, D, Reddy, S, Belani, C, Drabick, JJ & Vogelzang, NJ 2018, 'Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers', European Urology Focus, vol. 4, no. 1, pp. 94-97. https://doi.org/10.1016/j.euf.2016.06.011
Yin, M, Joshi, M, Meijer, RP, Glantz, M, Holder, S, Harvey, HA, Kaag, M, Van De Putte, EEF, Horenblas, S & Drabick, JJ 2016, 'Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis', Oncologist, vol. 21, no. 6, pp. 708-715. https://doi.org/10.1634/theoncologist.2015-0440
Joshi, M, Vasekar, M, Grivas, P, Emamekhoo, H, Hsu, JA, Miller, VA, Stephens, PJ, Ali, SM, Ross, JS, Zhu, J, Warrick, J, Drabick, JJ, Holder, SL, Kaag, M, Li, M & Pal, SK 2016, 'Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma', Oncotarget, vol. 7, no. 32, pp. 52442-52449. https://doi.org/10.18632/oncotarget.9449
Yin, M, Wang, W, Rosenberg, J, Kaag, MG, Joshi, M, Holder, S, Tuanquin, L & Drabick, J 2016, 'Targeted Therapy in Collecting Duct Carcinoma of the Kidney: A Case Report and Literature Review', Clinical Genitourinary Cancer, vol. 14, no. 2, pp. e203-e206. https://doi.org/10.1016/j.clgc.2015.11.008

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)